Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma

被引:31
作者
Yoo, Changhoon [1 ]
Yoon, Dok Hyun [1 ]
Kim, Shin [1 ]
Huh, Jooryung [2 ]
Park, Chan-Sik [2 ]
Park, Chan-Jeong [3 ]
Lee, Sang-Wook [4 ]
Suh, Cheolwon [1 ]
机构
[1] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Dept Pathol, Asan Med Ctr, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Dept Lab Med, Asan Med Ctr, Seoul 138736, South Korea
[4] Univ Ulsan, Coll Med, Dept Radiat Oncol, Asan Med Ctr, Seoul 138736, South Korea
关键词
beta-2; microglobulin; mantle cell lymphoma; prognosis; INDEX;
D O I
10.1002/hon.2188
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although serum beta-2 microglobulin (B2M) has been suggested as a prognostic factor for mantle cell lymphoma (MCL), additional data are necessary to confirm its role. Between November 2005 and July 2014, a total of 52 patients with MCL were identified from the database of Asan Medical Center, Seoul, Korea. Pretreatment serum B2M information was available in 50 patients (96%). Overall survival (OS) was compared according to the serum B2M level with a cut-off value of 2.5mg/L. The median MCL international prognostic index (MIPI) score was 5.84 (range 4.72-7.80), and the median biologic MIPI (MIPI-b) score was 6.27 (4.93-8.47). Pretreatment serum B2M was elevated in 30 patients (60%) and was significantly related to advanced stage (p=0.02) and high MIPI (p=0.03) and MIPI-b (p=0.03) scores. With median follow-up duration of 29.8months (range 0.8-87.0months), the median OS was 56.2months [95% confidence interval (CI) 36.6-75.9months] in all patients, and serum B2M was significantly associated with OS (p=0.001). In multivariate analyses adjusted for MIPI or MIPI-b scores and rituximab, elevated serum B2M was significantly associated with poor OS (when adjusting MIPI, hazard ratio=26.4, 95% CI 2.9-241.3, p=0.004; when adjusting MIPI-b, hazard ratio=20.1, 95% CI 2.4-170.1, p=0.006). Thus, pretreatment serum B2M may be an independent and significant prognostic factor in patients with MCL. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:22 / 27
页数:6
相关论文
共 18 条
[1]   Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study [J].
Abrahamsson, Anna ;
Albertsson-Lindblad, Alexandra ;
Brown, Peter N. ;
Baumgartner-Wennerholm, Stefanie ;
Pedersen, Lars M. ;
D'Amore, Francesco ;
Nilsson-Ehle, Herman ;
Jensen, Paw ;
Pedersen, Michael ;
Geisler, Christian H. ;
Jerkeman, Mats .
BLOOD, 2014, 124 (08) :1288-1295
[2]  
Aprile von Hohenstaufen K, 2013, BRIT J HAEMATOL, V162, P465
[3]   Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Dreyling, M. ;
Geisler, C. ;
Hermine, O. ;
Kluin-Nelemans, H. C. ;
Le Gouill, S. ;
Rule, S. ;
Shpilberg, O. ;
Walewski, J. ;
Ladetto, M. .
ANNALS OF ONCOLOGY, 2014, 25 :83-92
[4]   Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project [J].
Federico, Massimo ;
Bellei, Monica ;
Marcheselli, Luigi ;
Luminari, Stefano ;
Lopez-Guillermo, Armando ;
Vitolo, Umberto ;
Pro, Barbara ;
Pileri, Stefano ;
Pulsoni, Alessandro ;
Soubeyran, Pierre ;
Cortelazzo, Sergio ;
Martinelli, Giovanni ;
Martelli, Maurizio ;
Rigacci, Luigi ;
Arcaini, Luca ;
Di Raimondo, Francesco ;
Merli, Francesco ;
Sabattini, Elena ;
McLaughlin, Peter ;
Solal-Celigny, Philippe .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4555-4562
[5]   SMALL SUBUNIT OF HL-A ANTIGENS IS BETA2-MICROGLOBULIN [J].
GREY, HM ;
KUBO, RT ;
COLON, SM ;
POULIK, MD ;
CRESSWELL, P ;
SPRINGER, T ;
TURNER, M ;
STROMINGER, JL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1973, 138 (06) :1608-1612
[6]   A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma [J].
Hoster, Eva ;
Dreyling, Martin ;
Klapper, Wolfram ;
Gisselbrecht, Christian ;
van Hoof, Achiel ;
Kluin-Nelemans, Hanneke C. ;
Pfreundschuh, Michael ;
Reiser, Marcel ;
Metzner, Bernd ;
Einsele, Hermann ;
Peter, Norma ;
Jung, Wolfram ;
Woermann, Bernhard ;
Ludwig, Wolf-Dieter ;
Duehrsen, Ulrich ;
Eimermacher, Hartmut ;
Wandt, Hannes ;
Hasford, Joerg ;
Hiddemann, Wolfgang ;
Unterhalt, Michael .
BLOOD, 2008, 111 (02) :558-565
[7]   Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network [J].
Hoster, Eva ;
Klapper, Wolfram ;
Hermine, Olivier ;
Kluin-Nelemans, Hanneke C. ;
Walewski, Jan ;
van Hoof, Achiel ;
Trneny, Marek ;
Geisler, Christian H. ;
Di Raimondo, Francesco ;
Szymczyk, Michal ;
Stilgenbauer, Stephan ;
Thieblemont, Catherine ;
Hallek, Michael ;
Forstpointner, Roswitha ;
Pott, Christiane ;
Ribrag, Vincent ;
Doorduijn, Jeanette ;
Hiddemann, Wolfgang ;
Dreyling, Martin H. ;
Unterhalt, Michael .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) :1338-1346
[8]   Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics [J].
Jares, Pedro ;
Colomer, Dolors ;
Campo, Elias .
NATURE REVIEWS CANCER, 2007, 7 (10) :750-762
[9]   Transplantation in patients with diffuse mantle cell lymphoma in first disease remission the prognostic value of β2-microglobulin and the tumor score [J].
Khouri, IF ;
Saliba, RM ;
Okoroji, GJ ;
Acholonu, SA ;
Champlin, RE .
CANCER, 2003, 98 (12) :2630-2635
[10]   Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL network [J].
Klapper W. ;
Hoster E. ;
Determann O. ;
Oschlies I. ;
van der Laak J. ;
Berger F. ;
Bernd H.W. ;
Cabeçadas J. ;
Campo E. ;
Cogliatti S. ;
Leo Hansmann M. ;
Kluin P.M. ;
Kodet R. ;
Krivolapov Y.A. ;
Loddenkemper C. ;
Stein H. ;
Möller P. ;
Barth T.E.F. ;
Müller-Hermelink K. ;
Rosenwald A. ;
Ott G. ;
Pileri S. ;
Ralfkiaer E. ;
Rymkiewicz G. ;
van Krieken J.H. ;
Wacker H.H. ;
Unterhalt M. ;
Hiddemann W. ;
Dreyling M. .
Journal of Hematopathology, 2009, 2 (2) :103-111